- Home
- GLMD vs IMRN Comparison
GLMD vs IMRN Comparison
Compare GLMD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- IMRN
- Stock Information
- Founded
- GLMD 2000
- IMRN 1994
- Country
- GLMD Israel
- IMRN Australia
- Employees
- GLMD N/A
- IMRN N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- IMRN Health Care
- Exchange
- GLMD Nasdaq
- IMRN Nasdaq
- Market Cap
- GLMD 7.9M
- IMRN 9.2M
- IPO Year
- GLMD 2014
- IMRN N/A
- Fundamental
- Price
- GLMD $1.49
- IMRN $1.80
- Analyst Decision
- GLMD Hold
- IMRN Strong Buy
- Analyst Count
- GLMD 1
- IMRN 1
- Target Price
- GLMD N/A
- IMRN $5.00
- AVG Volume (30 Days)
- GLMD 164.0K
- IMRN 64.9K
- Earning Date
- GLMD 09-02-2025
- IMRN 09-08-2025
- Dividend Yield
- GLMD N/A
- IMRN N/A
- EPS Growth
- GLMD N/A
- IMRN N/A
- EPS
- GLMD N/A
- IMRN N/A
- Revenue
- GLMD N/A
- IMRN $4,048,286.00
- Revenue This Year
- GLMD N/A
- IMRN N/A
- Revenue Next Year
- GLMD N/A
- IMRN N/A
- P/E Ratio
- GLMD N/A
- IMRN N/A
- Revenue Growth
- GLMD N/A
- IMRN 82.90
- 52 Week Low
- GLMD $1.15
- IMRN $1.50
- 52 Week High
- GLMD $23.80
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- GLMD 44.36
- IMRN 54.17
- Support Level
- GLMD $1.35
- IMRN $1.62
- Resistance Level
- GLMD $1.59
- IMRN $1.93
- Average True Range (ATR)
- GLMD 0.11
- IMRN 0.11
- MACD
- GLMD 0.00
- IMRN 0.01
- Stochastic Oscillator
- GLMD 44.56
- IMRN 58.06
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.